West Cancer Center

« back to all trials

ENDOMETRIAL: ANY STAGE: ADJUVANT: CHEMO-NAIVE: HER2+: NRG-GY026

Title

NRG Endometrial HER2+

Study Title

Site Link

NCT05256225

Malignancy

Endometrial, uterine

Stage

Stage 3

Disease Setting

Adjuvant/Post-surgical

Line Of Therapy

1st Line

Investigational Agent

Trastuzumab or trastuzumab/pertuzumab

Drug Class

HER2 antibody

Todd Tillmanns, MD

Sponsor

NRG Oncology

Phase

Phase 3

Status

Open to Enrollment

Key Eligibility Criteria

Key Eligibility Criteria Details

FIGO 2009 stage IA-IVB non-recurrent, chemo-naive, HER2-positive endometrial serous carcinoma or carcinosarcoma
Measurable or no-measurable disease allowed
ECOG PS 0-2
No prior chemo, biologic therapy, or targeted thearpy for treatment of endometrial cancer
No prior radiation therapy for endometrial cancer
No planned radiation
No significant cardiac, lung, or intercurrent illness
Patients with prior treatment with hormonal therapy are allowed

Objective

Assessment Frequency

Assessment Frequency 2

Assessment Frequency Link

Path

Serous carcinoma or carcinosarcoma

Dosing Frequency

Control Agents

Study Protocol

Randomized

Yes